Evidence map›Paper›PMID 36047906›Full record

ReviewTranscription

BRD4: a general regulator of transcription elongation.

Elisabeth Altendorfer, Yelizaveta Mochalova, Andreas Mayer

Open access · hybridAbstract readReview
In one paragraph

Review in Transcription. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Targeting BRD4-A Promising Therapeutic Option for Glioblastoma?International journal of molecular sciences · 2026
    Review
  9. Article
  10. Article
  11. AI-Assisted Drug Re-Purposing for Human Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elisabeth AltendorferOtto-Warburg-Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Yelizaveta MochalovaOtto-Warburg-Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Andreas MayerOtto-Warburg-Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Max Planck Institute for Molecular Genetics · DEFreie Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription elongation by RNA polymerase II (Pol II) has emerged as a regulatory hub in gene expression. A key control point occurs during early transcription elongation when Pol II pauses in the promoter-proximal region at the majority of genes in mammalian cells and at a large set of genes in

Indexed as

Nuclear ProteinsTranscription FactorsAnimalsDrosophilaMammalsPromoter Regions, GeneticRNA Polymerase IITranscription, GeneticNuclear ProteinsRNA Polymerase IITranscription FactorsBET proteinsBRD4promoter-proximal pausingPROTACRNA polymerase IItranscription elongation

Identifiers

PMID36047906
PMCPMC9467588
OpenAlexW4294044322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.